Auranofin is administered orally. Common dosing ranges from tablets, and the oral dosage usually recommended for adult patients with rheumatoid arthritis is 6 mg once a day; however, this dose must be adjusted based on a patient’s condition and response to treatment and any co-morbidities present.
It is crucial to follow the prescription of the doctor regarding the dosage because too much or too little may determine efficacy or increase susceptibility to side effects. Usually, the dose is adjusted according to how you respond to the medicine and experience side effects.
Auranofin acts through the immune system to combat inflammation of rheumatoid arthritis. The immune system attacks the body’s own joints, leading to inflammation, pain, and sometimes damage in patients suffering from RA.
While the drug’s precise mechanisms of action are not fully understood, it is supposed that the gold part within the drug changes the function of certain cells of the immune system which are implicated in the autoimmune reaction.
Gold salts such as auranofin appear to inhibit some cytokines (proteins that carry out immune responses) and modify the functions of immune cells, T-cells and macrophages, thus reducing inflammation, lessening destruction of the joint, and possibly slowing the progression of rheumatoid arthritis.
Unlike any other medication, side effects are bound to occur with the use of auranofin. Some of these include;
Gastrointestinal issues which include nausea, diarrhea, stomach upset, and abdominal discomfort.
Skin reactions: rash, itching, or increased sensitivity to the skin.
Headache: some patients may experience headache with auranofin.
Mouth ulcers: some patients may experience mouth sores or lesions.
Serious but rare include:
Allergic reaction: is a condition characterized by swelling of the face, lips, tongue,
dysfunction, which might be associated with the first signs of damage to the liver.
Liver problems: Some people experience increased liver enzymes or liver among patients who already have kidney problems.
If you experience any severe or unusual symptoms, see a healthcare provider as soon as possible.
Auranofin should be administered with caution. Treatment with auranofin is not recommended for everybody. The most important warnings include:
Blood Disorders: Auranofin can cause blood abnormalities, potentially resulting in reduced numbers of blood cells, with increased risks of infection and bleeding. Blood tests may be needed regularly for monitoring.
Liver or Kidney Problems: Patients who have a history of liver or kidney disease need to use auranofin with caution. It may need dosage adjustment or monitoring of the function of the kidneys/liver during treatment.
Pregnancy and Breastfeeding: Auranofin is a pregnancy category C drug. It can cause harm to a fetus. Their use is restricted in case of required pregnancy unless absolutely unavoidable. They are not advisable with breastfeeding.
The typical daily dose of auranofin in rheumatoid arthritis is 6 mg, though adjustments according to the individual’s response are common. Some patients will need more or less of the drug based on their disease and their physician’s recommendations.
In some patients, the doctor might increase or reduce the dose if adverse effects arise or if there is suspicion of blood cell reductions or organ impairment.
The treatment can be continued for many years, but regular follow-up reviews must be attended to check for side effects, which include blood tests to keep a lookout for signs of bone marrow suppression or liver and kidney function disorders.
Auranofin is a prescription medication; it should be taken only under the supervision of a qualified healthcare provider.
It is also important that a patient discusses any medical background, including pre-existing conditions, with the doctor before starting auranofin.